Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 9, 2012, Pages 1487-1492

  Abdelwahab, S ^a   Azmy, A ^a   Abdel Aziz, H ^a   Salim, H ^a   Mahmoud, A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Cetuximab; Chemotherapy; Elderly; Irinotecan; MCRC

Indexed keywords

ATROPINE; CETUXIMAB; DEXAMETHASONE; GRANISETRON; IRINOTECAN; LOPERAMIDE; ONDANSETRON;

ABDOMINAL PAIN; ACNE; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HUMAN; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CAMPTOTHECIN; COLONIC NEOPLASMS; DIARRHEA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84866736742     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1229-8     Document Type: Article

References (30)

1. Andoh T, Ishii K, Suzuki Y et al (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-5569
2. Audisio RA, Veronesi P, Ferrario L et al (1997) Elective surgery for gastrointestinal tumors in the elderly. Ann Oncol 8:317-326
3. Balducci L (2000) Geriatric oncology: challenges for the new century. Eur J Cancer 36:1741-1754
4. Charlson ME, Pompei P, Ales K, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383
5. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
6. Garcia-Alfonso P, Munoz-Martin AJ, Alvarez-Suarez S et al (2010) Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. Br J Cancer 103(10):1524-1528
7. Goldberg RM (2005) Advances in the treatment of metastatic colorectal cancer. Oncologist 10(Suppl 3):40-48
8. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23-30
9. Grothey A, Sargent D, Goldberg RM, Schmoll H-J (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214
10. Humblet Y, Peeters M, Gelderblom H (2007) Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacydata from the EVEREST study. In: ECCO 14th European cancer conference, Barcelona, Spain, 23-27 September 2007 (abstract 3017)
11. Jehn CF, Boning L, Kröning H et al (2012) Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 106:274-278
12. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96
13. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048
14. Kaplan ES, Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
15. Lièvre A, Samalin E, Mitry E et al (2009) Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 9:347
16. Lim R, Sun Y, Im SA et al (2011) Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J Gastroenterol 17(14):1879-1888
17. Martín-Martorell P, Roselló S, Rodriguez-Braun E et al (2008) Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 99(3):455-458
18. Meyerhardt JA, Mayer RJ (2005) Therapy for colorectal cancer. N Engl J Med 352:476-487
19. Pfeiffer P, Nielsen D, Yilmaz M et al (2007a) Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 46:697-701
20. Pfeiffer P, Qvortrup C, Eriksen JG (2007b) The current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 26:3661-3678
21. Pfeiffer P, Nielsen D, Bjerregaard J et al (2008) Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 19:1141-1145
22. Roca JM, Alonso V, Pericay C et al (2011) Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer. Chemotherapy 56(2):142-146
23. Saltz LB, Meropol NJ, Loehrer PJ Sr (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201-1208
24. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26(14):2311-2319
25. Tabernero J, Cervantes A, Martinelli E et al (2006) Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharma-cokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. ASCO annual meeting proceedings part I, vol 24 (abstract 3085)
26. Tabernero J, Pfeiffer P, Cervantes A (2008) Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective more convenient alternative to weekly administration? Oncologist 13:113-119
27. Tabernero J, Ciardiello F, Rivera F et al (2010) Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 21(7):1537-1545
28. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
29. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse. Sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
30. Vincenzi B, Santini D, Rabitti C et al (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94(6):792-797